Neurohormonal markers of clinical outcome in cardiovascular disease: Is endothelin the best one?

Journal of Cardiovascular Pharmacology

Volumn 32, Issue SUPPL. 2, 1998, Pages

  Monge, Juan Carlos ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

ACE inhibitors; Atherosclerosis; Congestive heart failure; Endothelin 1; Fosinopril

Indexed keywords

ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; FOSINOPRIL; NEUROHORMONE; NORADRENALIN; RENIN; VASOCONSTRICTOR AGENT;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DISEASE MARKER; HEART HYPERTROPHY; HORMONE BLOOD LEVEL; HUMAN; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; SMOOTH MUSCLE FIBER;

EID: 0031722746     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199800004-00006     Document Type: Conference Paper

References (51)

1. Yanagisawa M, Kunhara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
2. Webb DJ, Monge JC, Rebelink TJ, Yengijawa M. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci 1998;19:5-8.
3. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-7.
4. Bakris GL, Fairbanks R, Traish AM. Arginine vasopressin stimulates human mesangial cell production of endothelin. J Clin Invest 1991;87:1158-64.
5. Shimada K, Takahashi M, Tanzawa K. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 1994;269:18275-8.
6. Xu D, Emoto N, Giaid A, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994;78:473-85.
7. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995;270:15262-8.
8. Rubanyi GM, Botelho LH. Endothelins. FASEB J 1991;5:2713-20.
9. Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994;368:703-10.
10. Kurihara Y, Kurihara H, Oda M, et al. Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. J Clin Invest 1995;96:293-300.
11. Hilal-Dandan R, Urasawa K, Brunton LL. Endothelin inhibits adenylate cyclase and stimulates phosphoinositide hydrolysis in adult cardiac myocytes. J Biol Chem 1992;267:10620-4.
12. Ito H, Hirata Y, Hiroe M, et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991;69:209-15.
13. Shubeita HE, McDonough PM, Harris AN, et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 1990; 265:20555-62.
14. Mantymaa P, Leppaluoto J, Ruskoaho H. Endothelin stimulates basal and stretch-induced atrial natriuretic peptide secretion from the perfused rat heart. Endocrinology 1990;126:587-95.
15. Yoshimi H, Hirata Y, Fukuda Y, et al. Regional distribution of immunoreactive endothelin in rats. Peptides 1989;10:805-8.
16. Yoshizawa T, Shinmi O, Giaid A, et al. Endothelin: a novel peptide in the posterior pituitary system. Science 1990;247:462-4.
17. Shinmi O, Kimura S, Yoshizawa T, et al. Presence of endothelin-1 in porcine spinal cord: isolation and sequence determination. Biochem Biophys Res Commun 1989;162:340-6.
18. MacCumber MW, Ross CA, Snyder SH. Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proc Natl Acad Sci USA 1990;87:2359-63.
19. Giaid A, Gibson SJ, Ibrahim BN, et al. Endothelin 1, an endothelium-derived peptide, is expressed in neurons of the human spinal cord and dorsal root ganglia. Proc Natl Acad Sci USA 1989;86: 7634-8.
20. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348:730-2.
21. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990;348:732-5.
22. Hori S, Komatsu Y, Shigemoto R, Mizuno N, Nakanishi S. Distinct tissue distribution and cellular localization of two messenger ribonucleic acids encoding different subtypes of rat endothelin receptors. Endocrinology 1992;130:1885-95.
23. Margulies KB, Hildebrand FL Jr, Lerman A, Perrella MA, Burnett JC Jr. Increased endothelin in experimental heart failure. Circulation 1990;82:2226-30.
24. Gauquelin G, Thibault G, Garcia R. Renal glomerular endothelial receptors in rats with high-output heart failure. Regul Pept 1991; 35:73-9.
25. Loffler BM, Roux S, Kalina B, Clozel M, Clozel JP. Influence of congestive heart failure on endothelin levels and receptors in rabbits. J Mol Cell Cardiol 1993;25:407-16.
26. Clavell AL, Mattingly MT, Stevens TL, et al. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest 1996;97:1286-92.
27. Sakai S, Miyauchi T, Sakurai T, et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 1996;93:1214-22.
28. Lerman A, Kubo SH, Tschumperlin LK, Burnett JC Jr. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol 1992;20:849-53.
29. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-9.
30. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85:504-9.
31. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-6.
32. Schiffrin EL, Intengan HD, Thibault G, Touyz RM. Clinical significance of endothelin in cardiovascular disease. Curr Opin Cardiol 1997;12:354-67.
33. Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens 1997;15:57-63.
34. Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996;28:652-5.
35. Rajagopalan S, Laursen JB, Borthayre A, et al. Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension 1997; 30:29-34.
36. Herizi A, Jover B, Bouriquet N, Mimran A. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension 1998;31:10-4.
37. Lerman A, Edwards BS, Hallet JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.
38. Ihling C, Gobel HR, Lippoldt A, et al. Endothelin-1-like immunoreactivity in human atherosclerotic coronary tissue: a detailed analysis of the cellular distribution of endothelin-1. J Pathol 1996; 179:303-8.
39. Ruetten H, Thiemermann C. Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamethasone. J Physiol Pharmacol 1997;48:675-88.
40. Kowala MC, Rose PM, Stein PD, et al. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 1995;146:819-26.
41. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:V15-16.
42. Rouleau JL, Packer M, Move L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994;24:583-91.
43. Omland T, Aavkvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9.
44. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16.
45. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994;89: 1573-9.
46. Pousset F, Isnard R, Lechat P, et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997;18:254-8.
47. Pacher R, Stanek B, Hulsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-41.
48. Grenier O, Pousset F, Isnard R, et al. Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure. Cardiorasc Drugs Ther 1996;10:561-5.
49. Townend J, Doran J, Jones S, Davies M. Effect of angiotensin converting enzyme inhibition on plasma endothelin in congestive heart failure. Int J Cardiol 1994;43:299-304.
50. Galatius-Jensen S, Wroblewski H, Emmeluth C, Bie P, Haunso S, Kastrup J. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor: fosinopril. Cardiovasc Res 1996;32:1148-54.
51. Zannad F, Chati Z, Guest M. Long-term comparison of fosinopril and enalapril in patients with mild to moderate chronic heart failure [Abstract]. Circulation 1997;96(suppl I):I-612.